Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000798595 | SCV000938218 | benign | Nemaline myopathy 2 | 2024-01-28 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001570111 | SCV001794330 | likely benign | not provided | 2020-10-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004027960 | SCV004979317 | uncertain significance | Inborn genetic diseases | 2023-12-14 | criteria provided, single submitter | clinical testing | The c.14572G>A (p.V4858I) alteration is located in exon 100 (coding exon 98) of the NEB gene. This alteration results from a G to A substitution at nucleotide position 14572, causing the valine (V) at amino acid position 4858 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000798595 | SCV001461654 | uncertain significance | Nemaline myopathy 2 | 2020-01-17 | no assertion criteria provided | clinical testing | |
Genome |
RCV000798595 | SCV001749433 | not provided | Nemaline myopathy 2 | no assertion provided | phenotyping only | Variant interpreted as Uncertain significance and reported on 04-09-2020 by Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. |